Skip to main content

Table 3 Cochrane’s risk of bias

From: Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials

Source of bias

Random sequence generation

Allocation concealment

Blinding of participants and personnel

Blinding of outcome assessment

Incomplete outcome data

Selective reporting

Other source of bias

Ling (2003)[33]

U

U

U

U

L

U

U

Ramachandran (2004)[34]

U

U

U

U

L

U

U

Derosa (2004)[35]

U

U

U

U

L

U

U

Gonzolez (2004)[36]

U

L

L

L

L

U

U

Rong (2004)[22]

U

U

U

U

L

U

U

Tang (2004)[37]

U

U

U

U

L

U

U

Yamanouchi (2005)[20]

L

L

L

U

L

U

U

Ning (2006)[38]

U

U

U

U

L

U

U

Wu (2007)[39]

U

U

U

U

L

U

U

Xu (2007)[40]

U

U

U

U

L

U

U

Li (2007)[41]

U

U

U

U

L

U

U

Wang (2009)[21]

U

U

U

U

L

U

U

Rahman (2011)[42]

U

U

U

U

L

U

U

Yoon (2011)[21]

U

U

U

U

L

U

U

Wang (2011)[43]

U

U

U

U

L

U

U

  1. Note: L, low risk of bias; U, unclear risk of bias; H, high risk of bias.